연구동향 분석

Identification of Patients with Recurrent Epithelial Ovarian Cancer Who Will Benefit from More Than Three Lines of Chemotherapy

설애란 임가원 정주연 김세익 이마리아 김희승 정현훈 김재원 박노현 송용상 2022년

논문상세정보
인용/피인용
' Identification of Patients with Recurrent Epithelial Ovarian Cancer Who Will Benefit from More Than Three Lines of Chemotherapy' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • Epithelial ovarian carcinoma
  • Drug therapy
  • Prognosis
  • Survival
  • recur-rence
  • treatment response
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
1,372 0

0.0%

' Identification of Patients with Recurrent Epithelial Ovarian Cancer Who Will Benefit from More Than Three Lines of Chemotherapy' 의 참고문헌

  • Trends in treatment during the last stages of life in end-stage gynecologic cancer patients who received active palliative chemotherapy : a comparative analysis of 10-year data in a single institution
    Jang TK [2018]
  • Trends in the aggressiveness of cancer care near the end of life
    Earle CC [2004]
  • The role of chemotherapy at the end of life : "when is enough, enough?"
  • The end of life costs for Medicare patients with advanced ovarian cancer
    Urban RR [2018]
  • The application of the Palliative Prognostic Index, charlson comorbidity index, and Glasgow Prognostic Score in predicting the life expectancy of patients with hematologic malignancies under palliative care
    Chou WC [2015]
  • The Palliative Prognostic Index : a scoring system for survival prediction of terminally ill cancer patients
    Morita T [1999]
  • Recurrent ovarian cancer : how important is it to treat to disease progression?
    Herzog TJ [2004]
  • Quality of end-of-life care in patients with hematologic malignancies : a retrospective cohort study
    Hui D [2014]
  • Quality of end-of-life care among rural Medicare beneficiaries with colorectal cancer
  • Prognostic disclosure to patients with cancer near the end of life
    Lamont EB [2001]
  • Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer : a Gynecologic Oncology Group study
    Ozols RF [2003]
  • Palliative chemotherapy : historical perspective, applications, and controversies
    Browner I [2005]
  • Ovarian cancer
    Jayson GC [2014]
  • Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube
  • Nomogram for predicting individual survival after recurrence of advanced-stage, high-grade ovarian carcinoma
    Rose PG [2019]
  • New response evaluation criteria in solid tumours : revised RECIST guideline(version 1. 1)
  • NCCN Guidelines(R) insights: palliative care, version 2.2021
    Dans M [2021]
  • Impact of timing and setting of palliative care referral on quality of end-of-life care in cancer patients
    Hui D [2014]
  • Global cancer statistics 2020 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
    Sung H [2021]
  • Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
    Bray , F. , [2018]
  • Estimates of worldwide burden of cancer in 2008 : GLOBOCAN 2008
    Ferlay J [2010]
  • Erlotinib in previously treated non-small-cell lung cancer
    Shepherd FA [2005]
  • Early onset neutropenia : a useful predictor of chemosensitivity and favorable prognosis in patients with serous ovarian cancer
    He Y [2020]
  • Determinants of aggressive end-of-life care for Taiwanese cancer decedents, 2001 to 2006
    Tang ST [2009]
  • Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
  • Chemotherapy use, performance status, and quality of life at the end of life
  • Chemotherapy use at the end of life : an analysis of the decision making process
    Giorgi F [2004]
  • Chemotherapy given near the end of life by community oncologists for advanced non-small cell lung cancer
  • According to the 2002 WHO definition of palliative care
  • A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer